|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 24
Zeitschriftenartikel
Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J.
(2022):
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 386, Nr. 6: S. 556-567
Müller, V.; Banys-Paluchowski, M.; Friedl, T. W. P.; Fasching, P. A.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; Rübner, M.; Hoffmann, O.; Müller, L.; Janni, W.; Wimberger, P.; Jäger, B.; Pantel, K.; Riethdorf, S.; Harbeck, N. und Fehm, T.
(2021):
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
In: Esmo Open, Bd. 6, Nr. 6
Konecny, G. E.; Hendrickson, A. E. Wahner; Davidson, T. M.; Winterhoff, B. J.; Ma, S.; Mahner, S.; Sehouli, J.; Fasching, P. A.; Feisel-Schwickardi, G.; Poelcher, M.; Roman, L. D.; Rody, A.; Karlan, B. Y.; Mullany, S. A.; Chen, H.; Ray-Coquard, I. L.; Provencher, D. M.; Yachnin, A.; Cottu, P. H.; Glaspy, J. A.; Haluska, P. und Slamon, D. J.
(2021):
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
In: Gynecologic Oncology, Bd. 163, Nr. 3: S. 465-472
Harbeck, N.; Rastogi, P.; Martin, M.; Tolaney, S. M.; Shao, Z. M.; Fasching, P. A.; Huang, C. S.; Jaliffe, G. G.; Tryakin, A.; Goetz, M. P.; Rugo, H. S.; Senkus, E.; Testa, L.; Andersson, M.; Tamura, K.; Del Mastro, L.; Steger, G. G.; Kreipe, H.; Hegg, R.; Sohn, J.; Guarneri, V.; Cortes, J.; Hamilton, E.; Andre, V.; Wei, R.; Barriga, S.; Sherwood, S.; Forrester, T.; Munoz, M.; Shahir, A.; San Antonio, B.; Nabinger, S. C.; Toi, M.; Johnston, S. R. D. und O'Shaughnessy, J.
(2021):
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
In: Annals of Oncology, Bd. 32, Nr. 12: S. 1571-1581
Hack, C. C.; Haeberle, L.; Brucker, S. Y.; Janni, W.; Volz, B.; Loehberg, C. R.; Hartkopf, A. D.; Walter, C.-B.; Baake, G.; Fridman, A.; Malter, W.; Würstlein, R.; Harbeck, N.; Hoffmann, O.; Kuemmel, S.; Martin, B.; Thomssen, C.; Graf, H.; Wolf, C.; Lux, M. P.; Bayer, C. M.; Rauh, C.; Almstedt, K.; Gass, P.; Heindl, F.; Brodkorb, T.; Willer, L.; Lindner, C.; Kolberg, H-C; Krabisch, P.; Weigel, M.; Steinfeld-Birg, D.; Kohls, A.; Brucker, C.; Schulz, V.; Fischer, G.; Pelzer, V.; Rack, B.; Beckmann, M. W.; Fehm, T.; Rody, A.; Maass, N.; Hein, A.; Fasching, P. A. und Nabieva, N.
(2020):
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
In: Breast, Bd. 50: S. 11-18
Millstein, J.; Budden, T.; Goode, E. L.; Anglesio, M. S.; Talhouk, A.; Intermaggio, M. P.; Leong, H. S.; Chen, S.; Elatre, W.; Gilks, B.; Nazeran, T.; Volchek, M.; Bentley, R. C.; Wang, C.; Chiu, D. S.; Kommoss, S.; Leung, S. C. Y.; Senz, J.; Lum, A.; Chow, V.; Sudderuddin, H.; Mackenzie, R.; George, J.; Fereday, S.; Hendley, J.; Traficante, N.; Steed, H.; Koziak, J. M.; Kobel, M.; McNeish, I. A.; Goranova, T.; Ennis, D.; Macintyre, G.; De Silva, D. Silva; Ramon y Cajal, T.; Garcia-Donas, J.; Hernando Polo, S.; Rodriguez, G. C.; Cushing-Haugen, K. L.; Harris, H. R.; Greene, C. S.; Zelaya, R. A.; Behrens, S.; Fortner, R. T.; Sinn, P.; Herpel, E.; Lester, J.; Lubinski, J.; Oszurek, O.; Toloczko, A.; Cybulski, C.; Menkiszak, J.; Pearce, C. L.; Pike, M. C.; Tseng, C.; Alsop, J.; Rhenius, V.; Song, H.; Jimenez-Linan, M.; Piskorz, A. M.; Gentry-Maharaj, A.; Karpinskyj, C.; Widschwendter, M.; Singh, N.; Kennedy, C. J.; Sharma, R.; Harnett, P. R.; Gao, B.; Johnatty, S. E.; Sayer, R.; Boros, J.; Winham, S. J.; Keeney, G. L.; Kaufmann, S. H.; Larson, M. C.; Luk, H.; Hernandez, B. Y.; Thompson, P. J.; Wilkens, L. R.; Carney, M. E.; Trabert, B.; Lissowska, J.; Brinton, L.; Sherman, M. E.; Bodelon, C.; Hinsley, S.; Lewsley, L. A.; Glasspool, R.; Banerjee, S. N.; Stronach, E. A.; Haluska, P.; Ray-Coquard, I; Mahner, S.; Winterhoff, B.; Slamon, D.; Levine, D. A.; Kelemen, L. E.; Benitez, J.; Chang-Claude, J.; Gronwald, J.; Wu, A. H.; Menon, U.; Goodman, M. T.; Schildkraut, J. M.; Wentzensen, N.; Brown, R.; Berchuck, A.; Chenevix-Trench, G.; DeFazio, A.; Gayther, S. A.; Garcia, M. J.; Henderson, M. J.; Rossing, M. A.; Beeghly-Fadiel, A.; Fasching, P. A.; Orsulic, S.; Karlan, B. Y.; Konecny, G. E.; Huntsman, D. G.; Bowtell, D. D.; Brenton, J. D.; Doherty, J. A.; Pharoah, P. D. P. und Ramus, S. J.
(2020):
Prognostic gene expression signature for high-grade serous ovarian cancer.
In: Annals of Oncology, Bd. 31, Nr. 9: S. 1240-1250
Nabieva, N.; Fehm, T.; Haeberle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H. -C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J. -U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Popovic, M.; Kuhn, T.; Wolf, C.; Vollert, H. -W.; Breitbach, G. -P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Noesselt, T.; Fischer, G.; Henschen, S.; Praetz, T.; Heyl, V.; Kuehn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; Tesch, H.; Mundhenke, C.; Hein, A.; Hack, C. C.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kuemmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A.
(2018):
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
In: European Journal of Cancer, Bd. 96: S. 82-90
Witzel, I.; Laakmann, E.; Weide, R.; Neunhoeffer, T.; Park-Simon, T. -J.; Schmidt, M.; Fasching, P. A.; Hesse, T.; Polasik, A.; Mohrmann, S.; Wuerschmidt, F.; Schem, C.; Bechtner, C.; Würstlein, R.; Fehm, T.; Moebus, V.; Burchardi, N.; Loibl, S. und Müller, V.
(2018):
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
In: European Journal of Cancer, Bd. 102: S. 1-9
Nabieva, N.; Kellner, S.; Fehm, T.; Häbrle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H.-C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J.-U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Fersis, N.; Kuhn, T.; Wolf, C.; Vollert, H.-W.; Breitbach, G.-P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Nösselt, T.; Fischer, G.; Henschen, S.; Prätz, T.; Heyl, V.; Kühn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; esch, H.; Mundhenke, C.; Hein, A.; Rauh, C.; Bayer, C. M.; Jacob, A.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kümmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A.
(2018):
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
In: Annals of Oncology, Bd. 29, Nr. 1: S. 186-192
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer.
In: Cancer Research, Bd. 77
Tzschaschel, M. L. J.; Rack, B.; Andergassen, U.; Friedl, T. W. P.; Schneeweiss, A.; Müller, V.; Tanja, F.; Pantel, K.; Gade, J.; Lorenz, R.; Rezai, M.; Tesch, H.; Soeling, U.; Polasik, A.; Alunni-Fabbroni, M.; Trapp, E. K.; Mahner, S.; Schindlbeck, C.; Lichtenegger, W.; Beckmann, M. W.; Fasching, P. A. und Janni, W.
(2017):
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 77
Tzschaschel, M. L. J.; Rack, B.; Majunke, L.; Trapp, E. K.; Mahner, S.; Fasching, P. A.; Fehm, T.; Schneeweiss, A.; Friedl, T. W. P.; Polasik, A.; Janni, W. und Alunni-Fabbroni, M.
(2017):
Profiling miRNA in high risk postoperative early breast cancer patients to detect possible association to correlation with immune system antitumor response.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer.
In: Cancer Research, Bd. 77
Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E. und Fasching, P. A.
(2017):
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis.
In: Cancer Research, Bd. 77
Hein, A.; Rack, B.; Li, L.; Ekici, A. B.; Reis, A.; Lux, M. P.; Cunningham, J. M.; Rübner, M.; Fridley, B. L.; Schneeweiss, A.; Tesch, H.; Lichtenegger, W.; Fehm, T.; Heinrich, G.; Rezai, M.; Beckmann, M. W.; Janni, W.; Weinshilboum, R. M.; Wang, L.; Fasching, P. A. und Häberle, L.
(2017):
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.
In: Geburtshilfe und Frauenheilkunde, Bd. 77, Nr. 6: S. 651-659
Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S.
(2016):
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
In: Oncology Research and Treatment, Bd. 39: S. 185
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer.
In: Oncology Research and Treatment, Bd. 39: S. 47
Schramm, A.; Friedl, T.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells.
In: Oncology Research and Treatment, Bd. 39: S. 46-47
Schröder, L.; Rack, B.; Sommer, H.; Koch, J. G.; Weissenbacher, T.; Janni, W.; Schneeweiss, A.; Rezai, M.; Lorenz, R.; Jäger, B.; Schramm, A.; Häberle, L.; Fasching, P. A.; Friedl, T. W. P.; Beckmann, M. W. und Scholz, C.
(2016):
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
In: Geburtshilfe und Frauenheilkunde, Bd. 76, Nr. 5: S. 542-550
Fasching, P. A.; Loibl, S.; Eidtmann, H.; Tesch, H.; Untch, M.; Hilfrich, J.; Schem, C.; Rezai, M.; Gerber, B.; Costa, S. D.; Blohmer, J. U.; Fehm, T. N.; Huober, J.; Liedtke, C.; Müller, V.; Nekljudova, V.; Weber, K.; Rack, B.; Rübner, M.; Wang, L.; Ingle, J. N.; Weinshilboum, R. M.; Minckwitz, G. von und Couch, F.
(2016):
BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study.
In: Cancer Research, Bd. 76
Benz, S. C.; Rabizadeh, S.; Cecchi, F.; Beckman, M. W.; Brucker, S. Y.; Hartmann, A.; Golovato, J.; Hembrough, T.; Janni, W.; Rack, B.; Sanborn, J. Z.; Schneeweiss, A.; Vaske, C. J.; Soon-Shiong, P. und Fasching, P. A.
(2016):
Integrating whole genome sequencing data with RNAseq, pathway analysis, and quantitative proteomics to determine prognosis after standard adjuvant treatment with trastuzumab and chemotherapy in primary breast cancer patients.
In: Cancer Research, Bd. 76
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer.
In: Cancer Research, Bd. 76
Schramm, A.; Fried, T. W. P.; Huober, J.; Jäger, B.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pante, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT study program - Personalized treatment in metastatic breast cancer based on circulating tumor cells.
In: Cancer Research, Bd. 76
Laessig, D.; Stemmler, H. J.; Vehling-Kaiser, U.; Fasching, P. A.; Melchert, F.; Koelbl, H.; Stauch, M.; Maubach, P.; Scharl, A.; Morack, G.; Meerpohl, H.; Weber, B.; Kalischefski, B. und Heinemann, Volker
(2007):
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
In: Oncology, Nr. 5-6: S. 407-414
[PDF, 150kB]